HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

diphenylcyclopropenone

strong contact sensitizer; a photosensitizing agent; RN given refers to parent cpd; structure given in first source
Also Known As:
2,3-diphenyl-2-cyclopropen-1-one; diphencyprone; diphenylcyclopropenone monohydrate
Networked: 170 relevant articles (20 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Thompson, John F: 5 articles (03/2014 - 05/2007)
2. Damian, Diona L: 5 articles (03/2014 - 05/2007)
3. Levis, William R: 4 articles (11/2015 - 05/2006)
4. Aghaei, Shahin: 3 articles (11/2008 - 01/2005)
5. Bergfeld, Wilma F: 2 articles (11/2015 - 09/2014)
6. Piliang, Melissa P: 2 articles (11/2015 - 09/2014)
7. Suárez-Fariñas, Mayte: 2 articles (01/2015 - 10/2014)
8. Correa da Rosa, Joel: 2 articles (01/2015 - 10/2014)
9. Gulati, Nicholas: 2 articles (01/2015 - 10/2014)
10. Krueger, James G: 2 articles (01/2015 - 10/2014)

Related Diseases

1. Alopecia Areata
2. Warts (Wart)
3. Melanoma (Melanoma, Malignant)
4. Neoplasm Metastasis (Metastasis)
05/01/2007 - "Topical immunotherapy with diphencyprone was an inexpensive and well-tolerated treatment for extensive cutaneous melanoma metastases in our patient unsuitable for other therapies."
11/01/2015 - "Diphencyprone (DPCP) is a potent topical sensitizing agent that has been used since the late 1970s by physicians for the treatment of alopecia areata (AA), viral warts (human papillomavirus) and cutaneous metastases of melanoma. "
01/01/2005 - "Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma."
11/01/2009 - "Diphencyprone (DPCP) immunotherapy is frequently used to treat cutaneous warts and alopecia areata, and we have previously reported the use of DPCP as a single agent to successfully treat extensive, radiotherapy-resistant melanoma metastases on the scalp. "
01/01/2015 - "Diphencyprone (DPCP) is a hapten that causes delayed-type hypersensitivity (DTH) reactions in human skin, and is used as a topical therapeutic for alopecia areata, warts, and cutaneous melanoma metastases.  We examined peak DTH reactions induced by DPCP (3 days post-challenge) by comprehensive gene expression and histological analysis.  To better understand how these DTH reactions naturally resolve, we compared our DPCP biopsies to those from patients with psoriasis vulgaris, a chronic inflammatory disease that does not resolve.  By both microarray and qRT-PCR, we found that psoriasis lesional skin has significantly lower expression of many negative immune regulators compared to peak DPCP reactions.  These regulators include: interleukin-10, cytotoxic T lymphocyte-associated 4 (CTLA4), programmed cell death 1 (PD1), programmed cell death 1 ligand 1 (PDL1), programmed cell death 1 ligand 2 (PDL2), and indoleamine 2,3-dioxygenase (IDO1).  Their decreased expression was confirmed at the protein level by immunohistochemistry.  To more completely determine the balance of positive vs. negative immune regulators in both DPCP reactions and psoriasis, we developed one comprehensive gene list for positive regulatory (inflammatory) genes, and another for negative regulatory (immunosuppressive) genes, through Gene Ontology terms and literature review.  With this approach, we found that DPCP reactions have a higher ratio of negative to positive regulatory genes (both in terms of quantity and expression levels) than psoriasis lesional skin.  These data suggest that the disease chronicity that distinguishes psoriasis from transient DTH reactions may be related to absence of negative immune regulatory pathways, and induction of these is therefore of therapeutic interest.  Further study of these negative regulatory mechanisms that are present in DPCP reactions, but not in psoriasis, could reveal novel players in the pathogenesis of chronic inflammation.  The DPCP system used here thus provides a tractable model for primary discovery of pathways potentially involved in immune regulation in peripheral tissues. "
5. Hypersensitivity (Allergy)

Related Drugs and Biologics

1. diphenylcyclopropenone
2. Dinitrochlorobenzene (DNCB)
3. Interleukin-10 (Interleukin 10)
4. Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)
5. squaric acid
6. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
7. Thymopentin
8. fexofenadine (Allegra)
9. Minoxidil (Rogaine)
10. Alopecia universalis

Related Therapies and Procedures

1. Immunotherapy
2. Cryotherapy (Therapy, Cold)
3. Immunomodulation
4. Phototherapy (Light Therapy)
5. Aftercare (After-Treatment)